Every 10-Q that enGene Therapeutics Inc. (ENGN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ENGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ENGN filings page.
enGene Therapeutics Inc. (ENGN) reported larger losses as it advances its lead gene-therapy candidate detalimogene in a pivotal Phase 2 LEGEND trial for bladder cancer. For the nine months ended July 31, 2026, net loss was $92.5 million with operating cash outflows of $78.3 million, and accumulated deficit reached $464.5 million.
Cash, cash equivalents and short-term marketable securities totaled about $266.3 million, and the company states this is expected to fund operating expenses and debt obligations for at least the next 12 months, helped by a November 2025 equity and pre-funded warrant raise and a new $125 million term loan facility of which $25 million is drawn. In June 2026, enGene approved a strategic restructuring that reduces its workforce by roughly 50% to conserve cash while focusing on completing LEGEND Cohort 1, adding a surfactant cohort, preparing a planned BLA submission in Q4 2026, and pre-commercial activities for a potential 2027 launch, if detalimogene is approved.
enGene Therapeutics reported a net loss of $30.2M for the quarter and $60.0M for the six months ended April 30, 2026, driven by research and development and growing general and administrative costs. Operating cash outflow was $59.4M over six months.
The company held $29.8M in cash and cash equivalents and $255.2M in marketable securities, with total assets of $307.5M and shareholders’ equity of $255.2M. Management expects this liquidity to fund operations and debt obligations for at least 12 months, but anticipates needing additional capital thereafter.
enGene expanded its debt facility to up to $125M, drawing $25M, and raised equity through a late-2025 public offering and pre-funded warrants. Subsequent to quarter-end, it announced a workforce reduction of about 50% and a strategic restructuring to preserve cash while advancing its LEGEND trial of detalimogene and preparing for a potential BLA filing.
enGene Holdings Inc. reported a larger quarterly net loss as it continues to invest heavily in its lead bladder cancer gene therapy, detalimogene. For the three months ended January 31, 2026, net loss was $29.8M, compared with $24.6M a year earlier, driven by higher research and development and general and administrative expenses.
To support development and potential commercialization, enGene significantly strengthened its balance sheet. Cash, cash equivalents and marketable securities rose to $312.5M from $202.3M at October 31, 2025, helped by a late‑2025 equity offering and a new term loan facility of up to $125M, of which $25M is drawn. The company believes this funding will cover operating and debt needs for at least the next 12 months as it advances its pivotal LEGEND trial and prepares a planned Biologics License Application in the second half of 2026.